| Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:森林图/亚组分析图;Extended Data Fig. 2:生活质量量表图。 | PMID 39354196PMC11645259 | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.Int J Hematol | PMID 39361234PMC11588829 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial.Lancet Respir Med | PMID 39366400无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.Int J Clin Oncol | PMID 39382718PMC11588814 | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| High efficacy of red light photodynamic therapy with 10 % aminolevulinic acid gel irrespective of the extent of keratinocyte atypia in actinic keratosis - exploratory post-hoc analysis of three pivotal phase III trials.Photodiagnosis Photodyn Ther | PMID 39384092无 PMCID | 2024-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm | PMID 39393045PMC11488827 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost.Radiother Oncol | PMID 39395667无 PMCID | 2024-Dec | 0.95 | This is a randomized Phase III trial in human breast cancer patients, and it reports primary results. However, it is excluded because the intervention is non-drug (radiotherapy schedules), and the primary endpoint is a toxicity outcome (breast induration), not a time-to-event efficacy endpoint like OS, PFS, or DFS. | 待处理 |
| Efficacy and safety of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazin-3-carboxamide 1,1-dioxide, a rapid-acting meloxicam formulation, for analgesia after orthopaedic surgery under general anaesthesia: a randomized controlled trial.Inflammopharmacology | PMID 39397127无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.Gynecol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39413557无 PMCID | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews.Clin Ther | PMID 39414418无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of neutralizing antibody response as a correlate of protection against symptomatic SARS-CoV-2 infections after administration of two doses of the CoronaVac inactivated COVID-19 vaccine: A phase III randomized controlled trial.J Infect | PMID 39423875无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder.CNS Drugs | PMID 39424742PMC11543726 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study.Eur J Cancer | PMID 39427441无 PMCID | 2024-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial.Radiol Med | PMID 39436588无 PMCID | 2024-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial.Nat Med | PMID 39468363PMC11645260 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of 1.5% levofloxacin otic solution in treating acute otitis externa: A post hoc analysis of ENT103-3001, a multicenter randomized double-blind parallel-group placebo-controlled phase III study in otitis media with persistent otorrhea.Auris Nasus Larynx | PMID 39476787无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study.Contemp Clin Trials | PMID 39477206无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39486165无 PMCID | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39489924无 PMCID | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial.Semin Arthritis Rheum | PMID 39509838无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.Eur J Cancer | PMID 39509846PMC11622473 | 2024-Dec | 0.95 | This is an original Phase III randomized trial in oncology with a drug intervention. However, it is not eligible because its primary endpoint is chemotherapy completion rate (a categorical/completion endpoint), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. No time-to-event data, Kaplan-Meier estimates, or hazard ratios are reported in the abstract. | 待处理 |
| Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39520835无 PMCID | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.Lancet Haematol | PMID 39521008无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years.J Dermatolog Treat | PMID 39522957无 PMCID | 2024-Dec | 0.95 | The study is a randomized Phase III trial of baricitinib for atopic dermatitis (not oncology/malignant-neoplasm), and its primary efficacy endpoint is a categorical response proportion (vIGA-AD 0/1), not a time-to-event outcome. | 待处理 |
| Long-term safety and tolerability of hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE-CIDP 3 trial.J Peripher Nerv Syst | PMID 39523874PMC11625974 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.Future Oncol | PMID 39530627PMC11789469 | 2024-Dec | 0.90 | The study is a randomized Phase III drug trial in oncology, but the abstract does not explicitly report a primary/key secondary time-to-event efficacy endpoint like OS, PFS, DFS, etc., with Kaplan-Meier curves or hazard ratios. It reports response rates and a 6-month PFS rate, but without formal time-to-event analysis data. | 待处理 |
| Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial.Drugs | PMID 39542995PMC11652401 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39549720无 PMCID | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.Lancet Oncol | PMID 39551064PMC11726348 | 2024-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39557058无 PMCID | 2024-Dec | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR Study.Clin Pharmacokinet | PMID 39565561PMC11649739 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial.Lancet Child Adolesc Health | PMID 39572123无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.Lancet Neurol | PMID 39577921无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.Nature疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39604725无 PMCID | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.EBioMedicine | PMID 39631145PMC11663783 | 2024-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials.Cephalalgia | PMID 39648617无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52.J Dermatolog Treat | PMID 39658004无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of 4-hydroxy 2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazin-3-carboxamide 1,1-dioxide, a fast-acting meloxicam formulation, on moderate-to-severe pain following abdominal surgery: A phase III randomized controlled trial.Clin Transl Sci | PMID 39660482PMC11632392 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic value of radiologic and pathological response in colorectal cancer liver metastases upon systemic induction treatment: subgroup analysis of the CAIRO5 trial.ESMO Open | PMID 39667310PMC11697041 | 2024-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2.Circ Cardiovasc Interv | PMID 39689189无 PMCID | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.Eur Respir J | PMID 39326921PMC11618813 | 2024-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39282906无 PMCID | 2024-Nov-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39602630无 PMCID | 2024-Nov-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.Blood Cancer J | PMID 39609425PMC11605113 | 2024-Nov-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.J Pediatric Infect Dis Soc | PMID 39351798PMC11599144 | 2024-Nov-27 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.J Immunother Cancer | PMID 39608979PMC11603811 | 2024-Nov-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Consent-Related Outcomes in the Alteplase Compared to Tenecteplase Trial.Neurology | PMID 39509663PMC11558543 | 2024-Nov-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Lack of Effect of Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: A Short Report from the InTENSE Trial.Toxins (Basel) | PMID 39728768PMC11728757 | 2024-Nov-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39580202无 PMCID | 2024-Nov-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial.Clin Infect Dis | PMID 38913574PMC11581693 | 2024-Nov-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |